Setipiprant
Setipiprant is an oral medication currently in the testing phase for the treatment of hair loss. Originally developed as a treatment for allergic rhinitis, researchers have uncovered its potential effectiveness in addressing androgenetic alopecia.
In simple terms, the mechanism of action of setipiprant involves blocking the prostaglandin D2 receptor 2 (DP2), which, in turn, prevents PGD2 from triggering hair loss. PGD2 is currently believed to be associated with various pathological responses related to allergies, inflammation, and asthma.
In the field of alopecia, setipiprant has not gained widespread popularity as it is still undergoing phase 2 testing and has not yet been made available on the market. Nevertheless, it is eagerly awaited, and some individuals have been able to access setipiprant online for the purpose of conducting “scientific research.”
Is it effective against hair loss?
Regarding the relationship between setipiprant and hair loss, we have some noteworthy studies:
2012: A study on PGD2 and its link to androgenetic alopecia
In a study conducted by Lui A. Garza and colleagues, it was demonstrated that prostaglandin D2 (PGD2) could inhibit hair growth and was found in abundance in individuals with androgenetic alopecia.
From this, it becomes evident that there is a detrimental association between PGD2 and hair loss. Therefore, the notion of using a PGD2 inhibitor like setipiprant gains significance.
2021: Phase 2 Study: Setipiprant vs. Finasteride
Numerous scientific studies were conducted during the phase 2 trials of setipiprant. However, we only have access to the most recent study from 2021.
In this 32-week study, the effects of 1000mg setipiprant were compared to 1mg finasteride in individuals with androgenetic alopecia. The results were highly disappointing, as setipiprant demonstrated no positive impact on hair loss.
Consequently, the study concluded that setipiprant had no efficacy in treating androgenetic alopecia.
Concluding thoughts and verdict
Despite its effectiveness in treating allergic rhinitis, setipiprant has demonstrated no efficacy in phase 2 scientific studies for androgenetic alopecia. Therefore, I advise against having overly optimistic expectations for this medication.
However, it’s worth noting that setipiprant is still in the experimental phase. There is a possibility of obtaining more favorable results by either increasing the dosage or combining it with another compound. We will need to await further research and developments in the years ahead to gauge its potential effectiveness.
Precautions & side Effects
Potential side effects include nausea, drowsiness, anxiety, dry mouth, and elevated liver enzymes.